Last reviewed · How we verify

NCT02183818

Integrative-omics of the Disordered COPD Small Airway Epithelium

Completed Last updated 28 May 2021
What this trial tests

trial in Smoking in 42 participants. Completed in 15 October 2020.

Timeline
6 April 2015
Primary endpoint
17 November 2016
15 October 2020

Quick facts

Lead sponsorWeill Medical College of Cornell University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment42
Start date6 April 2015
Primary completion17 November 2016
Estimated completion15 October 2020
Sites1 location across United States

Conditions studied

Sponsor

Weill Medical College of Cornell University

Who can join

Adults 18 to 100, any sex, with Smoking or COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We aim to use an integrated network systems approach to analyze certain existing small airway epithelium (SAE) omic data sets at the genetic, epigenetic (methylation), gene expression, microRNA and metabolomic levels, to develop an initial model of network connectivities and key network pressure points relevant to SAE biology in health and disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A roadmap towards personalized immunology.
    Delhalle S, Bode SFN, Balling R, Ollert M, et al · · 2018 · cited 42× · PMID 29423275 · DOI 10.1038/s41540-017-0045-9

Verify or expand the search:

Other recruiting trials for Smoking

Currently open trials in the same condition.

Other Weill Medical College of Cornell University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02183818.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing